Literature DB >> 29245186

Endothelial Dysfunction in Early Systemic Lupus Erythematosus Patients and Controls Without Previous Cardiovascular Events.

Mara Taraborelli1, Edoardo Sciatti2, Ivano Bonadei2, Vincenzo Terlizzi2, Micaela Fredi1, Roberta Zani1, Giovanni Cancarini2, Angela Tincani2, Franco Franceschini1, Enrico Vizzardi2, Ilaria Cavazzana1.   

Abstract

OBJECTIVE: To assess the prevalence and risk factors for endothelial dysfunction detected by peripheral artery tonometry in systemic lupus erythematosus patients with early disease without cardiovascular disease and risk factors.
METHODS: All the consecutive adult lupus patients, with a disease duration <5 years, seen in our hospital from December 2014 to March 2016 were considered. We excluded patients with any history of cardiovascular disease or risk factors possibly affecting peripheral artery tonometry. Enrolled patients were matched for sex, age, body mass index, and blood pressure with healthy controls with the same exclusion criteria. Patients and controls received a transthoracic Doppler echocardiogram and an evaluation of endothelial function by peripheral artery tonometry.
RESULTS: Twenty patients (100% female) with a median disease duration of 14 months (range 1-58 months), a mean ± SD age of 42 ± 15 years, and a mean ± SD age at diagnosis of 40 ± 16 years were enrolled and matched with 20 controls. Peripheral artery tonometry showed a significantly higher prevalence of endothelial dysfunction (P = 0.003) and vascular stiffness (P = 0.02), while echocardiography detected a significantly higher prevalence of left ventricular concentric remodeling (P = 0.003), grade I diastolic dysfunction (P = 0.047), and subclinical increase of filling pressures (P = 0.039) in lupus patients compared to controls. Among lupus patients, no features were associated with endothelial dysfunction.
CONCLUSION: A high rate of endothelial dysfunction and vascular stiffness occurs in early lupus patients without cardiovascular risk factors and disease. Larger studies are needed to confirm our results and to look for patients' characteristics possibly associated with these abnormalities.
© 2017, American College of Rheumatology.

Entities:  

Mesh:

Year:  2018        PMID: 29245186     DOI: 10.1002/acr.23495

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  5 in total

Review 1.  Cardiovascular disease in systemic lupus erythematosus.

Authors:  Maureen McMahon; Richard Seto; Brian J Skaggs
Journal:  Rheumatol Immunol Res       Date:  2021-12-15

2.  Choroidal thickness changes in systemic lupus erythematosus patients.

Authors:  Arnaldo Dias-Santos; Joana Tavares Ferreira; Sofia Pinheiro; João Paulo Cunha; Marta Alves; Ana Luísa Papoila; Maria Francisca Moraes-Fontes; Rui Proença
Journal:  Clin Ophthalmol       Date:  2019-08-20

Review 3.  Systemic Lupus Erythematosus and Cardiovascular Disease.

Authors:  Surajkumar B Jha; Ana P Rivera; Gabriela Vanessa Flores Monar; Hamza Islam; Sri Madhurima Puttagunta; Rabia Islam; Sumana Kundu; Ibrahim Sange
Journal:  Cureus       Date:  2022-02-08

Review 4.  Endothelial Dysfunction in Systemic Lupus Erythematosus and Systemic Sclerosis: A Common Trigger for Different Microvascular Diseases.

Authors:  Liala Moschetti; Silvia Piantoni; Enrico Vizzardi; Edoardo Sciatti; Mauro Riccardi; Franco Franceschini; Ilaria Cavazzana
Journal:  Front Med (Lausanne)       Date:  2022-04-08

5.  Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.

Authors:  Sarfaraz A Hasni; Sarthak Gupta; Michael Davis; Elaine Poncio; Yenealem Temesgen-Oyelakin; Philip M Carlucci; Xinghao Wang; Mohammad Naqi; Martin P Playford; Rishi R Goel; Xiaobai Li; Ann J Biehl; Isabel Ochoa-Navas; Zerai Manna; Yinghui Shi; Donald Thomas; Jinguo Chen; Angélique Biancotto; Richard Apps; Foo Cheung; Yuri Kotliarov; Ashley L Babyak; Huizhi Zhou; Rongye Shi; Katie Stagliano; Wanxia Li Tsai; Laura Vian; Nathalia Gazaniga; Valentina Giudice; Shajia Lu; Stephen R Brooks; Meggan MacKay; Peter Gregersen; Nehal N Mehta; Alan T Remaley; Betty Diamond; John J O'Shea; Massimo Gadina; Mariana J Kaplan
Journal:  Nat Commun       Date:  2021-06-07       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.